Dikalova_et_al_Hypertension_2020_76(6):1980-1991.
Hypertension remains a major health problem in Western Societies, and blood pressure is poorly controlled in a third of patients despite use of multiple drugs. Mitochondrial dysfunction contributes to hypertension and mitochondria-targeted agents can potentially improve treatment of hypertension. We have proposed that mitochondrial oxidative stress produces reactive dicarbonyl lipid peroxidation products isolevuglandins (isoLGs) and that scavenging of mitochondrial isoLG improves vascular function and reduces hypertension. To test this hypothesis, we have studied the accumulation of mitochondrial isoLGs-protein adducts in patients with essential hypertension and angiotensin II model of hypertension using mass spectrometry and Western blot analysis. The therapeutic potential of targeting mitochondrial isoLG was tested by the novel mitochondria-targeted isoLG scavenger, mito2HOBA. Mitochondrial isoLGs in arterioles from hypertensive patients were 250% greater than in arterioles from normotensive subjects, and ex vivo mito2HOBA treatment of arterioles from hypertensive subjects increased deacetylation of a key mitochondrial antioxidant, superoxide dismutase 2 (SOD2). In human aortic endothelial cells stimulated with angiotensin II plus TNFα, mito2HOBA reduced mitochondrial superoxide and cardiolipin oxidation, a specific marker of mitochondrial oxidative stress. In angiotensin II-infused mice, mito2HOBA diminished mitochondrial isoLGs-protein adducts, raised Sirt3 mitochondrial deacetylase activity, reduced vascular superoxide, increased endothelial nitric oxide, improved endothelium-dependent relaxation, and attenuated hypertension. Mito2HOBA preserved mitochondrial respiration, protected ATP production, and reduced mitochondrial permeability pore opening in angiotensin II-infused mice. These data support the role of mitochondrial isoLGs in endothelial dysfunction and hypertension. We conclude that scavenging of mitochondrial isoLGs may have therapeutic potential in treatment of vascular dysfunction and hypertension.
Funding
Sirtuin 3 Impairment and SOD2 Acetylation in Oxidative Stress and Hypertension
National Heart Lung and Blood Institute
Find out more...Targeting Mitochondrial Cyclophilin D in Vascular Oxidative Stress and Hypertension
National Heart Lung and Blood Institute
Find out more...The Role of Inflammation in Cardiovascular Disease
National Heart Lung and Blood Institute
Find out more...Targeting Sirt3 Expression in Vascular Dysfunction and Hypertension
American Heart Association
Find out more...